Results 181 to 190 of about 113,580 (306)

Discovery of natural product derivative triptolidiol as a direct NLRP3 inhibitor by reducing K63‐specific ubiquitination

British Journal of Pharmacology, EarlyView.
▪ Background and Purpose NLRP3 is up‐regulated in inflammatory and autoimmune diseases. The development of NLRP3 inhibitors is challenged by the identification of compounds with distinct mechanisms of action avoiding side effects and toxicity. Triptolide is a natural product with multiple anti‐inflammatory activities, but a narrow therapeutic window ...
Mo‐Yu Ding, Chengqing Ning, Shao‐Ru Chen, Hao‐Ran Yin, Jing Xu, Ying Wang   +5 more
wiley   +1 more source

Site‐specific m6A‐miR‐494‐3p, not unmethylated miR‐494‐3p, compromises blood brain barrier by targeting tight junction protein 1 in intracranial atherosclerosis

British Journal of Pharmacology, EarlyView.
Background and Purpose Intracranial atherosclerosis is one of the most common causes of ischaemic stroke. However, there is a substantial knowledge gap on the development of intracranial atherosclerosis. Intracranial arteries are characterized by an upregulation of tight junctions between endothelial cells, which control endothelial permeability.
Tamar Woudenberg, M. Leontien van der Bent, Veerle Kremer, Ingeborg S. E. Waas, Mat J. A. P. Daemen, Reinier A. Boon, Paul H. A. Quax, A. Yaël Nossent   +7 more
wiley   +1 more source

Immunoengineering of a Photocaged 5´-triphosphate Oligoribonucleotide Ligand for Spatiotemporal Control of RIG-I Activation in Cancer. [PDF]

Angew Chem Int Ed Engl
Lewash SA, McKenney VR, Wuebben C, Ludwig J, Hosni R, Radzey D, Toma MI, Bartok E, Schlee M, Zillinger T, Heckel A, Hartmann G.   +11 more
europepmc   +1 more source

Advancing antihypertensive drug development

British Journal of Pharmacology, EarlyView.
Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment resistance, adverse effects, and adherence challenges.
Fay Pu, Yanrong Liu, Fozia Zahir Ahmed, Xin Wang, Darren Green, Hongyuan Zhang   +5 more
wiley   +1 more source

Targets and Gene Therapy of ALS (Part 1). [PDF]

Int J Mol Sci
Shiryaeva O, Tolochko C, Alekseeva T, Dyachuk V.   +3 more
europepmc   +1 more source

Steroid‐Modulated Transcription Synergistically Forms DNA Double‐Strand Breaks With Topoisomerase II Inhibitor

Cancer Science, EarlyView.
Through our exploration of the synergistic effects of drug combinations for potential clinical applications, we found that steroids potentiate the anticancer effects of etoposide, a topoisomerase II inhibitor. Steroids, when combined with etoposide, increase DNA double‐strand breaks not via DNA repair inhibition but transcriptional modulation ...
Ying Zhao, Tetsuro Hisayoshi, Doudou Zhang, Saaya Suzuki, Takashi Watanabe, Atsuo Kobayashi, Qianqian Guo, Yukihide Momozawa, Takashi Shimokawa, Shunsuke Kato, Yoshio Miki, Shigeaki Sunada   +11 more
wiley   +1 more source

Robust Photocleavable Linkers for DNA Synthesis: Enabling Visible Light-Triggered Antisense Oligonucleotide Release in 3D DNA Nanocages. [PDF]

Biomacromolecules
Leung HM, Chan HY, Klimezak M, Liu LS, Karam P, Specht A, Bolze F, Lo PK.   +7 more
europepmc   +1 more source

Longitudinal Visual Biomarkers in Dominant Optic Atrophy: A Systematic Review and Meta‐Analysis

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background Dominant Optic Atrophy (DOA) causes slowly progressive visual decline usually beginning in childhood. As new therapies come to clinical trial, the choice of biomarkers to be used as clinical trial endpoints has become a critical question to be addressed. Methods We undertook a systematic review and meta‐analysis of studies reporting
Christopher A. Ovens, John R. Grigg, Clare L. Fraser   +2 more
wiley   +1 more source

Synthetic-polymer-assisted antisense oligonucleotide delivery: targeted approaches for precision disease treatment. [PDF]

Beilstein J Nanotechnol
Alvarez AC, Maguire D, Brannigan RP.
europepmc   +1 more source

Why, how and in whom should we measure levels of lipoprotein(a): A review of the latest evidence and clinical implications

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Lipoprotein(a) [Lp(a)] is a genetically determined, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve disease (CAVD). Despite robust evidence from epidemiological and genetic studies, Lp(a) remains underrecognised in clinical practice due to challenges in measurement, lack of guideline familiarity ...
Alexander C. Razavi, Harpreet S. Bhatia, Roger S. Blumenthal, Michael D. Shapiro, Anurag Mehta   +4 more
wiley   +1 more source